Redefining Medicine with PDTs

What are PDTs? Prescription Digital Therapeutics – a new therapeutic class and similar to traditional biologics or drugs that directly treat serious diseases [read more]

Any discussion of issues that have gotten a lot worse because of the pandemic begins with the huge challenge the pandemic has posed to mental and psychological health & wellbeing. One of the dramatic manifestations of this has been a sharp rise in the incidence of substance abuse and addiction generally, and to opioids in particular.?New technologies are promising to help us better address these kinds of challenging health issues, and one of the most promising of these technologies is lead by Pear Therapeutics. The Institute for Health and Productivity Management is collaborating with the Pear Therapeutics to bring the added value of PDTs to employers facing this rising wave of Substance Use Disorder and Opioid Use Disorder in their work forces.?Additionally, Pear Therapeutics has a PDT product for Insomnia?that will be incorporated into the work of IHPM’s WorkPlace Center for Sleep Health & Wellbeing, at a time when sleep has taken on extra importance as foundational to a healthy immune system.

Treating Addiction with Prescription Digital Therapeutics [listen here]

Driven by the IHPM/WorkPlace Wellness Alliance mission to provide global insights for better work/health performance, over these next few weeks we are sharing the highlights from IHPM's Fall Forum 2021, held live at the beautiful?Sanctuary Camelback Mountain Resort?in Paradise Valley, Arizona. You can join us there in August 2022 for our next event. IHPM partnered with?AV Concepts?to provide these recordings.

Dr. Yuri Maricich, MBA is a licensed, board-certified physician, investor, clinical developer and strategist. He works to improve patient health and the healthcare system by investing in, advising, and providing leadership at innovative firms. At Pear Therapeutics, he leads the Clinical, Regulatory, and Quality groups as the Chief Medical Officer and Head of Development. He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission and review as well as Medical Affairs. In addition to overseeing subsequent pipeline programs across a broad-spectrum of disease areas, he has led the reSET, reSET-O, and Somryst programs.? Dr. Maricich completed his education and training at Harvard University (MBA), the University of Washington (MD, Medicine), the University of Notre Dame (Pre-Professional/Pre-Med/Philosophy), and the University of Virginia (Internal Medicine). Connect with Dr. Maricich here.

Dr. Fulton Velez, MS, MBA, is a physician and health economist with a background in clinical practice, and with more than 20 years of experience in clinical, health services, health economic, and real-world research spanning academia and industry.?He has worked across multiple therapeutic areas including metabolic disorders, infectious disease, endocrinology, reproductive health, neurology, ENT/allergy, and substance/opioid use disorders.? At Pear Therapeutics he is Head of Health Economics and Real-World Evidence. Dr. Velez has numerous health economic and clinical peer-reviewed publications and presentations at professional congresses.?He has held several leadership roles in health economics, including at three biomedical start-ups, where he has been responsible for leading product value discussions with payers to inform formulary coverage decisions. Connect with Dr. Velez here.